Moderna's 'surprise' IP court order could set up a big settlement for Roivant, Arbutus — analysts
The battle over who owns the patented lipid nanoparticle technology that carried the Covid-19 vaccines across the finish line and into millions of people’s arms remains in heated dispute. But a new court order adds an unexpected twist that could see the mRNA powerhouse Moderna paying a hefty sum to settle complaints from two smaller companies that originally licensed the LNP tech to Moderna.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.